Earlier this summer, the Food and Drug Administration (FDA) Oncology Drugs Advisory Committee (ODAC) announced a positive decision for Seattle Genetics’ Adcetris™ (brentuximab vedotin) in Hodgkin Lymphoma (HL) and Analplastic Large Cell Lymphoma (ALCL).
As Sally Church on Pharma Strategy Blog reported earlier this week, Seattle Genetics has just received fast track approval from the FDA for Adcetris™, a CD30-directed antibody drug-conjugate.
Using the company announced price of $13,500 per dose, Sally in her blog post analyzed the clinical trial data and treatment regimens to come up with a likely cost for a course of treatment in the range of $94,500 – $121,500.
Sally goes on to note that the “overall treatment cost will therefore be typically less than the $120K cost of treatment for BMS’s ipilimumab (Yervoy) in metastatic melanoma.”
The clinical data for Adcetris™ is impressive, and patients will most certainly benefit from the availability of this new treatment. Adcetris™ is the first antibody drug conjugate (ADC) technology to come to market.
You can read more about Sally’s analysis of the Adcetris™ price and other ADC products in the pipeline such as Roche’s T-DM1 on Pharma Strategy Blog.